3,762 reports of this reaction
2.9% of all LAMOTRIGINE EXTENDED RELEASE reports
#3 most reported adverse reaction
TOXICITY TO VARIOUS AGENTS is the #3 most commonly reported adverse reaction for LAMOTRIGINE EXTENDED RELEASE, manufactured by Advagen Pharma Limited. There are 3,762 FDA adverse event reports linking LAMOTRIGINE EXTENDED RELEASE to TOXICITY TO VARIOUS AGENTS. This represents approximately 2.9% of all 130,110 adverse event reports for this drug.
Patients taking LAMOTRIGINE EXTENDED RELEASE who experience toxicity to various agents should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TOXICITY TO VARIOUS AGENTS is a less commonly reported adverse event for LAMOTRIGINE EXTENDED RELEASE, but still significant enough to appear in the safety profile.
In addition to toxicity to various agents, the following adverse reactions have been reported for LAMOTRIGINE EXTENDED RELEASE:
The following drugs have also been linked to toxicity to various agents in FDA adverse event reports:
TOXICITY TO VARIOUS AGENTS has been reported as an adverse event in 3,762 FDA reports for LAMOTRIGINE EXTENDED RELEASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TOXICITY TO VARIOUS AGENTS accounts for approximately 2.9% of all adverse event reports for LAMOTRIGINE EXTENDED RELEASE, making it one of the most commonly reported side effect.
If you experience toxicity to various agents while taking LAMOTRIGINE EXTENDED RELEASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.